Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement - Adial Pharmaceuticals (NASDAQ:ADIL)

Core Viewpoint - Adial Pharmaceuticals, Inc. is implementing a 1-for-25 reverse stock split to strengthen its capital markets profile and comply with Nasdaq's minimum bid price requirement [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 27.8 million to about 1.1 million, while maintaining the ownership percentage of each shareholder [2]. - The reverse stock split will take effect on February 5, 2026, at 11:59 p.m. Eastern Time, with trading on a split-adjusted basis starting February 6, 2026 [1][2]. - There will be no change to the total number of authorized shares as per the Company's Certificate of Incorporation [2]. Group 2: Company Strategy and Future Outlook - The Company is optimistic about its future and is focused on advancing its lead product, AD04, a genetically targeted serotonin-3 receptor antagonist for treating Alcohol Use Disorder [3][4]. - Adial plans to conduct a new Phase 3 clinical trial program for AD04, targeting specific genotypes identified through its proprietary diagnostic genetic test [4]. - The Company believes that AD04 has the potential to treat other addictive disorders, including Opioid Use Disorder, gambling, and obesity [4].